New offerings enhance capabilities in ophthalmic pharmaceuticals.
- LTS introduces new ophthalmic drug delivery solutions.
- The expansion aims to enhance CDMO capabilities.
- New systems cater to the growing ophthalmic market.
LTS has announced the expansion of its Contract Development and Manufacturing Organization (CDMO) portfolio by introducing new ophthalmic drug delivery solutions. This move is designed to strengthen its offerings in the growing field of ophthalmic pharmaceuticals. With a focus on innovation, LTS aims to meet the evolving needs of the industry and improve patient care through advanced drug delivery.
The new ophthalmic drug delivery systems will allow LTS to support partners in developing and manufacturing a range of eye care products. These systems are tailored to improve the administration of medications and potentially enhance therapeutic outcomes for patients. This strategic expansion underlines LTS's commitment to providing high-quality pharmaceutical solutions in the ophthalmology sector.
